Conditions: 68Ga-FAPI PET/CT; Metastatic Adenoid Cystic Carcinoma
Intervention: Drug: 68Ga-FAPI
Sponsor: Peking Union Medical College Hospital
Recruiting
Feeds
4301 items (4301 unread) in 74 feeds
Acinar Cell Carcinoma
(73 unread)
Acinic Cell Carcinoma
(53 unread)
Adenoid Cystic Carcinoma
(264 unread)
Adrenal Gland Cancer
(299 unread)
Ampulla Of Vater
(55 unread)
Anal Cancer
(374 unread)
Angiosarcoma
(75 unread)
Appendix Cancer
(95 unread)
Bile Duct Cancer
(420 unread)
Brain and CNS
(464 unread)
Carcinoid
(70 unread)
Endocrine/Neuroendocrine
(637 unread)
Gall Bladder Cancer
(90 unread)
Hemangioendothelioma
(149 unread)
Hepatoblastoma
(67 unread)
Pancreas
(72 unread)
Phyllodes
(61 unread)
PMP and Mucinous Tumors
(79 unread)
Rhabdomyosarcoma
(96 unread)
Sarcoma
(808 unread)
Unread items (100)
PubMed - Adenoid Cystic Carcinoma
-
68Ga-FAPI PET/CT for the Detection of Adenoid Cystic Carcinoma(ACC)
Posted: August 12th, 2022, 2:00pm GMT
-
68Ga-FAPI PET/CT for the Detection of Adenoid Cystic Carcinoma(ACC)
Posted: August 12th, 2022, 2:00pm GMT
Conditions: 68Ga-FAPI PET/CT; Metastatic Adenoid Cystic Carcinoma
Intervention: Drug: 68Ga-FAPI
Sponsor: Peking Union Medical College Hospital
Recruiting -
A Study of SGN-B7H4V in Advanced Solid Tumors
Posted: January 18th, 2022, 3:00pm GMT
Conditions: Ovarian Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Triple Negative Breast Neoplasms; HER2 Negative Breast Neoplasms; Hormone Receptor Positive Breast Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Gallbladder Carcinoma; Adenoid Cystic Carcinoma
Intervention: Drug: SGN-B7H4V
Sponsor: Seagen Inc.
Recruiting -
A Study of SGN-B7H4V in Advanced Solid Tumors
Posted: January 18th, 2022, 3:00pm GMT
Conditions: Ovarian Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Triple Negative Breast Neoplasms; HER2 Negative Breast Neoplasms; Hormone Receptor Positive Breast Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Gallbladder Carcinoma; Adenoid Cystic Carcinoma
Intervention: Drug: SGN-B7H4V
Sponsor: Seagen Inc.
Recruiting -
Amivantamab in Adenoid Cystic Carcinoma
Posted: October 12th, 2021, 2:00pm GMT
Condition: Salivary Gland Cancer
Intervention: Drug: Amivantamab
Sponsor: Trisha Wise-Draper
Recruiting -
Amivantamab in Adenoid Cystic Carcinoma
Posted: October 12th, 2021, 2:00pm GMT
Condition: Salivary Gland Cancer
Intervention: Drug: Amivantamab
Sponsor: Trisha Wise-Draper
Recruiting -
9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma
Posted: August 18th, 2021, 2:00pm GMT
Conditions: Salivary Gland Cancer; Recurrent Salivary Gland Cancer; Metastatic Cancer; Adenoid Cystic Carcinoma
Interventions: Drug: 9-ING-41; Drug: Carboplatin
Sponsors: Glenn J. Hanna; Actuate Therapeutics Inc.
Recruiting -
9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma
Posted: August 18th, 2021, 2:00pm GMT
Conditions: Salivary Gland Cancer; Recurrent Salivary Gland Cancer; Metastatic Cancer; Adenoid Cystic Carcinoma
Interventions: Drug: 9-ING-41; Drug: Carboplatin
Sponsors: Glenn J. Hanna; Actuate Therapeutics Inc.
Recruiting -
Tyrosine Kinase Inhibitors in Metastastic Adenoid Cystic Carcinoma
Posted: July 23rd, 2021, 2:00pm GMT
Condition: Carcinoma, Adenoid Cystic
Intervention: Drug: EGFR-TK Inhibitor
Sponsor: Qingdao Central Hospital
Recruiting -
Tyrosine Kinase Inhibitors in Metastastic Adenoid Cystic Carcinoma
Posted: July 23rd, 2021, 2:00pm GMT
Condition: Carcinoma, Adenoid Cystic
Intervention: Drug: EGFR-TK Inhibitor
Sponsor: Qingdao Central Hospital
Recruiting -
AL101 Before Surgery for the Treatment of Notch Activated Adenoid Cystic Cancer
Posted: July 22nd, 2021, 2:00pm GMT
Conditions: Adenoid Cystic Carcinoma; Metastatic Adenoid Cystic Carcinoma
Interventions: Drug: AL101; Procedure: Therapeutic Conventional Surgery
Sponsor: M.D. Anderson Cancer Center
Recruiting -
AL101 Before Surgery for the Treatment of Notch Activated Adenoid Cystic Cancer
Posted: July 22nd, 2021, 2:00pm GMT
Conditions: Adenoid Cystic Carcinoma; Metastatic Adenoid Cystic Carcinoma
Interventions: Drug: AL101; Procedure: Therapeutic Conventional Surgery
Sponsor: M.D. Anderson Cancer Center
Recruiting -
Stereotactic Body Radiotherapy (SBRT) for Early Treatment of Oligometastatic Adenoid Cystic Carcinoma: The SOLAR Trial
Posted: May 12th, 2021, 2:00pm GMT
Conditions: Adenoid Cystic Carcinoma; Metastatic Adenoid Cystic Carcinoma
Interventions: Other: Standard of Care; Radiation: SBRT
Sponsors: Dana-Farber Cancer Institute; Adenoid Cystic Carcinoma Research Foundation; Gateway for Cancer Research
Recruiting -
Stereotactic Body Radiotherapy (SBRT) for Early Treatment of Oligometastatic Adenoid Cystic Carcinoma: The SOLAR Trial
Posted: May 12th, 2021, 2:00pm GMT
Conditions: Adenoid Cystic Carcinoma; Metastatic Adenoid Cystic Carcinoma
Interventions: Other: Standard of Care; Radiation: SBRT
Sponsors: Dana-Farber Cancer Institute; Adenoid Cystic Carcinoma Research Foundation; Gateway for Cancer Research
Recruiting -
9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma
Posted: April 5th, 2021, 2:00pm GMT
Conditions: Salivary Gland Carcinoma; Adenoid Cystic Carcinoma; Salivary Gland Cancer; Salivary Gland Neoplasms
Interventions: Drug: 9-ING-41; Drug: Carboplatin
Sponsor: Actuate Therapeutics Inc.
Withdrawn -
9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma
Posted: April 5th, 2021, 2:00pm GMT
Conditions: Salivary Gland Carcinoma; Adenoid Cystic Carcinoma; Salivary Gland Cancer; Salivary Gland Neoplasms
Interventions: Drug: 9-ING-41; Drug: Carboplatin
Sponsor: Actuate Therapeutics Inc.
Withdrawn -
Diagnosis of Adenoid Cystic Carcinoma on 68Ga-PSMA-617 PET-CT and Therapy With 177Lu-EB-PSMA-617
Posted: March 16th, 2021, 2:00pm GMT
Condition: Adenoid Cystic Carcinoma
Interventions: Drug: 68Ga-PSMA; Drug: 1.85GBq (50 mCi) of 177Lu-EB-PSMA-617
Sponsor: Peking Union Medical College Hospital
Recruiting -
Diagnosis of Adenoid Cystic Carcinoma on 68Ga-PSMA-617 PET-CT and Therapy With 177Lu-EB-PSMA-617
Posted: March 16th, 2021, 2:00pm GMT
Condition: Adenoid Cystic Carcinoma
Interventions: Drug: 68Ga-PSMA; Drug: 1.85GBq (50 mCi) of 177Lu-EB-PSMA-617
Sponsor: Peking Union Medical College Hospital
Recruiting -
Understanding the Burden of ACC Through the Eyes of Patients
Posted: January 13th, 2021, 3:00pm GMT
Condition: Adenoid Cystic Carcinoma
Intervention:
Sponsors: Ayala Pharmaceuticals, Inc,; Adenoid Cystic Carcinoma Research Foundation; Memorial Sloan Kettering Cancer Center; Hadassah Medical Organization; Engage Health Inc.
Unknown status -
Understanding the Burden of ACC Through the Eyes of Patients
Posted: January 13th, 2021, 3:00pm GMT
Condition: Adenoid Cystic Carcinoma
Intervention:
Sponsors: Ayala Pharmaceuticals, Inc,; Adenoid Cystic Carcinoma Research Foundation; Memorial Sloan Kettering Cancer Center; Hadassah Medical Organization; Engage Health Inc.
Unknown status -
All-trans Retinoic Acid (ATRA) in the Treatment of Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck
Posted: June 16th, 2020, 2:00pm GMT
Condition: Adenoid Cystic Carcinoma of the Head and Neck
Interventions: Drug: All-trans Retinoic Acid; Drug: VEGFR inhibitor; Drug: Chemotherapy
Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Recruiting -
All-trans Retinoic Acid (ATRA) in the Treatment of Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck
Posted: June 16th, 2020, 2:00pm GMT
Condition: Adenoid Cystic Carcinoma of the Head and Neck
Interventions: Drug: All-trans Retinoic Acid; Drug: VEGFR inhibitor; Drug: Chemotherapy
Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Recruiting -
Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer Patients
Posted: March 2nd, 2020, 3:00pm GMT
Conditions: Salivary Gland Cancer; Salivary Duct Carcinoma; Adenoid Cystic Carcinoma
Intervention: Drug: Lutetium-177-PSMA-I&T
Sponsors: Radboud University Medical Center; Dutch Cancer Society
Recruiting -
Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer Patients
Posted: March 2nd, 2020, 3:00pm GMT
Conditions: Salivary Gland Cancer; Salivary Duct Carcinoma; Adenoid Cystic Carcinoma
Intervention: Drug: Lutetium-177-PSMA-I&T
Sponsors: Radboud University Medical Center; Dutch Cancer Society
Recruiting -
P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)
Posted: January 31st, 2020, 3:00pm GMT
Conditions: Prostatic Neoplasms, Castration-Resistant; Neoplasms by Histologic Type; Neoplasms, Prostate; Prostate Cancer; Metastatic Castration-resistant Prostate Cancer; Neoplasms; Prostatic Neoplasms; Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Prostatic Disease; Salivary Gland Cancer; Salivary Gland Tumor; Adenoid Cystic Carcinoma; Salivary Duct Carcinoma; Mucoepidermoid Carcinoma; Acinic Cell Tumor
Interventions: Biological: P-PSMA-101 CAR-T cells; Drug: Rimiducid
Sponsor: Poseida Therapeutics, Inc.
Active, not recruiting -
P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)
Posted: January 31st, 2020, 3:00pm GMT
Conditions: Prostatic Neoplasms, Castration-Resistant; Neoplasms by Histologic Type; Neoplasms, Prostate; Prostate Cancer; Metastatic Castration-resistant Prostate Cancer; Neoplasms; Prostatic Neoplasms; Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Prostatic Disease; Salivary Gland Cancer; Salivary Gland Tumor; Adenoid Cystic Carcinoma; Salivary Duct Carcinoma; Mucoepidermoid Carcinoma; Acinic Cell Tumor
Interventions: Biological: P-PSMA-101 CAR-T cells; Drug: Rimiducid
Sponsor: Poseida Therapeutics, Inc.
Active, not recruiting -
Adenoid Cystic Carcinoma and Carbon Ion Only Irradiation
Posted: January 2nd, 2020, 3:00pm GMT
Condition: Adenoid Cystic Carcinoma
Interventions: Radiation: Carbon ion irradiation; Radiation: Bimodal irradiation
Sponsor: Heidelberg University
Recruiting -
Adenoid Cystic Carcinoma and Carbon Ion Only Irradiation
Posted: January 2nd, 2020, 3:00pm GMT
Condition: Adenoid Cystic Carcinoma
Interventions: Radiation: Carbon ion irradiation; Radiation: Bimodal irradiation
Sponsor: Heidelberg University
Recruiting -
Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers
Posted: December 24th, 2019, 3:00pm GMT
Conditions: Adenoid Cystic Carcinoma; Salivary Gland Cancer
Interventions: Drug: Lenvatinib; Drug: Pembrolizumab
Sponsors: Memorial Sloan Kettering Cancer Center; Merck Sharp & Dohme LLC; Eisai Inc.
Recruiting -
Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers
Posted: December 24th, 2019, 3:00pm GMT
Conditions: Adenoid Cystic Carcinoma; Salivary Gland Cancer
Interventions: Drug: Lenvatinib; Drug: Pembrolizumab
Sponsors: Memorial Sloan Kettering Cancer Center; Merck Sharp & Dohme LLC; Eisai Inc.
Recruiting -
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
Posted: October 28th, 2019, 2:00pm GMT
Conditions: Non Small Cell Lung Cancer; Advanced Solid Tumor; Metastatic Melanoma; Metastatic Head and Neck Carcinoma; Metastatic Renal Cell Carcinoma; Metastatic Colorectal Cancer; Sarcomas; Metastatic Prostate Cancer; Ovarian Cancer; Small Cell Lung Cancer; Metastatic Breast Cancer; Pancreas Cancer; Gastric Cancer; Esophageal Cancer; Gastroesophageal Junction Adenocarcinoma; Cervical Cancer; Adenoid Cystic Carcinoma; Salivary Gland Cancer; Urothelial Carcinoma
Interventions: Drug: ONC-392; Drug: Pembrolizumab
Sponsors: OncoC4, Inc.; National Cancer Institute (NCI)
Recruiting -
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
Posted: October 28th, 2019, 2:00pm GMT
Conditions: Non Small Cell Lung Cancer; Advanced Solid Tumor; Metastatic Melanoma; Metastatic Head and Neck Carcinoma; Metastatic Renal Cell Carcinoma; Metastatic Colorectal Cancer; Sarcomas; Metastatic Prostate Cancer; Ovarian Cancer; Small Cell Lung Cancer; Metastatic Breast Cancer; Pancreas Cancer; Gastric Cancer; Esophageal Cancer; Gastroesophageal Junction Adenocarcinoma; Cervical Cancer; Adenoid Cystic Carcinoma; Salivary Gland Cancer; Urothelial Carcinoma
Interventions: Drug: ONC-392; Drug: Pembrolizumab
Sponsors: OncoC4, Inc.; National Cancer Institute (NCI)
Recruiting -
A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC)
Posted: October 8th, 2019, 2:00pm GMT
Condition: Adenoid Cystic Carcinoma
Intervention: Drug: Rivoceranib
Sponsor: Elevar Therapeutics
Active, not recruiting -
A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC)
Posted: October 8th, 2019, 2:00pm GMT
Condition: Adenoid Cystic Carcinoma
Intervention: Drug: Rivoceranib
Sponsor: Elevar Therapeutics
Active, not recruiting -
The Registry of Oncology Outcomes Associated With Testing and Treatment
Posted: July 22nd, 2019, 2:00pm GMT
Conditions: Adenocarcinoma; Adenocystic Carcinoma; Anal Cancer; Appendix Cancer; Brain Tumor; Glioblastoma; Astrocytoma; Bile Duct Cancer; Cholangiocarcinoma; Bladder Cancer; Bone Cancer; Synovial Sarcoma; Chondrosarcoma; Liposarcoma; Sarcoma, Kaposi; Sarcoma,Soft Tissue; Sarcoma; Osteosarcoma; CNS Cancer; Brain Stem Neoplasms; Breast Cancer; Cervical Cancer; Colorectal Cancer; Rectal Cancer; Colon Cancer; Esophageal Cancer; Esophagus Cancer; Cancer of Colon; Pancreatic Cancer; Cancer of Pancreas; Testis Cancer; Testicular Cancer; Ureter Cancer; Renal Cell Carcinoma; Kidney Cancer; Gestational Trophoblastic Tumor; Head and Neck Neoplasms; Parotid Tumor; Larynx Cancer; Tongue Cancer; Pharynx Cancer; Salivary Gland Cancer; Acute Myeloid Leukemia; Chronic Myeloid Leukemia; Acute Lymphoblastic Leukemia; Multiple Myeloma; Non Hodgkin Lymphoma; Carcinoid Tumor; Lung Cancer; Neuroendocrine Tumors; Mesothelioma; Thyroid Cancer; Parathyroid Neoplasms; Adrenal Cancer; Small Bowel Cancer; Stomach Cancer; Liver Cancer; Hepatic Cancer; Melanoma; Skin Cancer; Unknown Primary Tumors; Uterine Cancer; Fallopian Tube Cancer; Ovarian Cancer; Prostate Cancer; Vaginal Cancer; Penile Cancer; Vulvar Cancer; Waldenstrom Macroglobulinemia; Cancer, Advanced; Thymus Cancer; Nasopharyngeal Carcinoma; Multiple Endocrine Neoplasia; Pheochromocytoma; Small Cell Carcinoma; Pulmonary Carcinoma
Interventions: Diagnostic Test: Biomarker Testing (L); Drug: Systemic Treatment (T); Other: Patient Reported Outcomes (P)
Sponsor: Taproot Health
Recruiting -
The Registry of Oncology Outcomes Associated With Testing and Treatment
Posted: July 22nd, 2019, 2:00pm GMT
Conditions: Adenocarcinoma; Adenocystic Carcinoma; Anal Cancer; Appendix Cancer; Brain Tumor; Glioblastoma; Astrocytoma; Bile Duct Cancer; Cholangiocarcinoma; Bladder Cancer; Bone Cancer; Synovial Sarcoma; Chondrosarcoma; Liposarcoma; Sarcoma, Kaposi; Sarcoma,Soft Tissue; Sarcoma; Osteosarcoma; CNS Cancer; Brain Stem Neoplasms; Breast Cancer; Cervical Cancer; Colorectal Cancer; Rectal Cancer; Colon Cancer; Esophageal Cancer; Esophagus Cancer; Cancer of Colon; Pancreatic Cancer; Cancer of Pancreas; Testis Cancer; Testicular Cancer; Ureter Cancer; Renal Cell Carcinoma; Kidney Cancer; Gestational Trophoblastic Tumor; Head and Neck Neoplasms; Parotid Tumor; Larynx Cancer; Tongue Cancer; Pharynx Cancer; Salivary Gland Cancer; Acute Myeloid Leukemia; Chronic Myeloid Leukemia; Acute Lymphoblastic Leukemia; Multiple Myeloma; Non Hodgkin Lymphoma; Carcinoid Tumor; Lung Cancer; Neuroendocrine Tumors; Mesothelioma; Thyroid Cancer; Parathyroid Neoplasms; Adrenal Cancer; Small Bowel Cancer; Stomach Cancer; Liver Cancer; Hepatic Cancer; Melanoma; Skin Cancer; Unknown Primary Tumors; Uterine Cancer; Fallopian Tube Cancer; Ovarian Cancer; Prostate Cancer; Vaginal Cancer; Penile Cancer; Vulvar Cancer; Waldenstrom Macroglobulinemia; Cancer, Advanced; Thymus Cancer; Nasopharyngeal Carcinoma; Multiple Endocrine Neoplasia; Pheochromocytoma; Small Cell Carcinoma; Pulmonary Carcinoma
Interventions: Diagnostic Test: Biomarker Testing (L); Drug: Systemic Treatment (T); Other: Patient Reported Outcomes (P)
Sponsor: Taproot Health
Recruiting -
A Trial of All-trans Retinoic Acid (ATRA) in Advanced Adenoid Cystic Carcinoma
Posted: June 27th, 2019, 2:00pm GMT
Condition: Adenoid Cystic Carcinoma
Intervention: Drug: Tretinoin
Sponsors: Dana-Farber Cancer Institute; The V Foundation; Adenoid Cystic Carcinoma Research Foundation
Completed -
A Trial of All-trans Retinoic Acid (ATRA) in Advanced Adenoid Cystic Carcinoma
Posted: June 27th, 2019, 2:00pm GMT
Condition: Adenoid Cystic Carcinoma
Intervention: Drug: Tretinoin
Sponsors: Dana-Farber Cancer Institute; The V Foundation; ACCRF
Completed -
Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
Posted: June 19th, 2019, 2:00pm GMT
Conditions: Metastatic Adenoid Cystic Carcinoma; Progressive Disease; Recurrent Adenoid Cystic Carcinoma
Interventions: Drug: Avelumab; Drug: Axitinib
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting -
Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
Posted: June 19th, 2019, 2:00pm GMT
Conditions: Metastatic Adenoid Cystic Carcinoma; Progressive Disease; Recurrent Adenoid Cystic Carcinoma
Interventions: Drug: Avelumab; Drug: Axitinib
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting -
A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies
Posted: March 22nd, 2019, 2:00pm GMT
Conditions: Relapsed/Refractory Advanced Solid Tumors; Relapsed/Refractory Diffuse Large B-cell Lymphoma; Relapsed/Refractory Myelodysplasia; Relapsed/Refractory Myelofibrosis; Adenoid Cystic Carcinoma; Relapsed/Refractory Mantle Cell Lymphoma; Relapsed/Refractory Acute Myeloid Leukemia; Refractory Chronic Myelomonocytic Leukemia
Intervention: Drug: PRT543
Sponsor: Prelude Therapeutics
Completed -
A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies
Posted: March 22nd, 2019, 2:00pm GMT
Conditions: Relapsed/Refractory Advanced Solid Tumors; Relapsed/Refractory Diffuse Large B-cell Lymphoma; Relapsed/Refractory Myelodysplasia; Relapsed/Refractory Myelofibrosis; Adenoid Cystic Carcinoma; Relapsed/Refractory Mantle Cell Lymphoma; Relapsed/Refractory Acute Myeloid Leukemia; Refractory Chronic Myelomonocytic Leukemia
Intervention: Drug: PRT543
Sponsor: Prelude Therapeutics
Completed -
APG-115 in Salivary Gland Cancer Trial
Posted: December 20th, 2018, 3:00pm GMT
Conditions: Malignant Salivary Gland Cancer; Salivary Gland Cancer
Interventions: Drug: APG-115; Drug: Carboplatin
Sponsors: University of Michigan Rogel Cancer Center; Ascentage Pharma Group Inc.
Recruiting -
APG-115 in Salivary Gland Cancer Trial
Posted: December 20th, 2018, 3:00pm GMT
Conditions: Malignant Salivary Gland Cancer; Salivary Gland Cancer
Interventions: Drug: APG-115; Drug: Carboplatin
Sponsors: University of Michigan Rogel Cancer Center; Ascentage Pharma Group Inc.
Recruiting -
A Study Of AL101 In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations
Posted: October 1st, 2018, 2:00pm GMT
Condition: Adenoid Cystic Carcinoma
Intervention: Drug: AL101
Sponsor: Ayala Pharmaceuticals, Inc,
Active, not recruiting -
A Study Of AL101 In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations
Posted: October 1st, 2018, 2:00pm GMT
Condition: Adenoid Cystic Carcinoma
Intervention: Drug: AL101
Sponsor: Ayala Pharmaceuticals, Inc,
Active, not recruiting -
Chidamide Combined With Cisplatin in Head and Neck Adenoid Cystic Carcinoma (HNACC)
Posted: August 21st, 2018, 2:00pm GMT
Conditions: Adenoid Cystic Carcinomas; Cisplatin
Intervention: Drug: Chidamide combined with cisplatin
Sponsor: Fudan University
Completed -
Chidamide Combined With Cisplatin in Head and Neck Adenoid Cystic Carcinoma (HNACC)
Posted: August 21st, 2018, 2:00pm GMT
Conditions: Adenoid Cystic Carcinomas; Cisplatin
Intervention: Drug: Chidamide combined with cisplatin
Sponsor: Fudan University
Completed -
Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Posted: June 14th, 2018, 2:00pm GMT
Conditions: Any Solid Tumors; Mesothelioma; Head and Neck Squamous Cell Carcinoma; Ovarian Cancer; Hepatocellular Carcinoma; Squamous Cell Carcinoma of Lung; Esophageal Cancer; Adenoid Cystic Carcinoma; Prostate Cancer; Cervical Cancer; Gastric Cancer; Melanoma; Acute Myeloid Leukemia; Non Hodgkin Lymphoma; Thymic Carcinoma and Thymoma; Progressor of Anti PD-1/PD-L1 Immunotherapy
Intervention: Drug: VMD-928 300 mg Tablet (ongoing); 100 mg Capsule (complete)
Sponsor: VM Oncology, LLC
Recruiting -
Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Posted: June 14th, 2018, 2:00pm GMT
Conditions: Any Solid Tumors; Mesothelioma; Head and Neck Squamous Cell Carcinoma; Ovarian Cancer; Hepatocellular Carcinoma; Squamous Cell Carcinoma of Lung; Esophageal Cancer; Adenoid Cystic Carcinoma; Prostate Cancer; Cervical Cancer; Gastric Cancer; Melanoma; Acute Myeloid Leukemia; Non Hodgkin Lymphoma; Thymic Carcinoma and Thymoma; Progressor of Anti PD-1/PD-L1 Immunotherapy
Intervention: Drug: VMD-928 300 mg Tablet (ongoing); 100 mg Capsule (complete)
Sponsor: VM Oncology, LLC
Recruiting -
Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies
Posted: February 6th, 2018, 3:00pm GMT
Conditions: Breast Cancer; Colorectal Cancer; Adenoid Cystic Carcinoma; Non-hodgkin Lymphoma; Glomus Tumor, Malignant; Hepatocellular Carcinoma; Osteosarcoma; T-ALL
Intervention: Drug: CB-103
Sponsor: Cellestia Biotech AG
Recruiting -
Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies
Posted: February 6th, 2018, 3:00pm GMT
Conditions: Breast Cancer; Colorectal Cancer; Adenoid Cystic Carcinoma; Non-hodgkin Lymphoma; Glomus Tumor, Malignant; Hepatocellular Carcinoma; Osteosarcoma; T-ALL
Intervention: Drug: CB-103
Sponsor: Cellestia Biotech AG
Recruiting -
PSMA-PET Imaging for Advanced ACC/SDC
Posted: October 24th, 2017, 2:00pm GMT
Conditions: Salivary Gland Cancer; Adenoid Cystic Carcinoma; Salivary Duct Carcinoma
Intervention: Diagnostic Test: PSMA-PET/CT scan
Sponsors: Radboud University Medical Center; Adenoid Cystic Carcinoma Research Foundation
Completed -
PSMA-PET Imaging for Advanced ACC/SDC
Posted: October 24th, 2017, 2:00pm GMT
Conditions: Salivary Gland Cancer; Adenoid Cystic Carcinoma; Salivary Duct Carcinoma
Intervention: Diagnostic Test: PSMA-PET/CT scan
Sponsors: Radboud University Medical Center; Adenoid Cystic Carcinoma Research Foundation
Completed -
Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC
Posted: September 25th, 2017, 2:00pm GMT
Conditions: Melanoma (Skin); Squamous Cell Carcinoma of the Skin; Carcinoma, Squamous Cell of Head and Neck; Carcinoma, Adenoid Cystic
Interventions: Biological: CV8102; Biological: CV8102 + anti-PD-1 therapy
Sponsors: CureVac; Syneos Health; Cromos Pharma LLC
Active, not recruiting -
MYPHISMO: MYB and PD-1 Immunotherapies Against Multiple Oncologies Trial
Posted: September 19th, 2017, 2:00pm GMT
Conditions: Colorectal Cancer; Adenoid Cystic Carcinoma
Interventions: Drug: TetMYB Vaccine; Drug: BGB-A317
Sponsor: Peter MacCallum Cancer Centre, Australia
Active, not recruiting -
MYPHISMO: MYB and PD-1 Immunotherapies Against Multiple Oncologies Trial
Posted: September 19th, 2017, 2:00pm GMT
Conditions: Colorectal Cancer; Adenoid Cystic Carcinoma
Interventions: Drug: TetMYB Vaccine; Drug: BGB-A317
Sponsor: Peter MacCallum Cancer Centre, Australia
Active, not recruiting -
Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer
Posted: May 10th, 2017, 2:00pm GMT
Conditions: Major Salivary Gland Carcinoma; Minor Salivary Gland Carcinoma; Recurrent Salivary Gland Carcinoma; Stage IV Major Salivary Gland Carcinoma; Stage IVA Major Salivary Gland Carcinoma; Stage IVB Major Salivary Gland Carcinoma; Stage IVC Major Salivary Gland Carcinoma
Interventions: Biological: Ipilimumab; Other: Laboratory Biomarker Analysis; Biological: Nivolumab
Sponsors: Northwestern University; Bristol-Myers Squibb; National Cancer Institute (NCI)
Unknown status -
Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
Posted: March 22nd, 2017, 2:00pm GMT
Condition: Adenoid Cystic Carcinoma
Interventions: Radiation: Radiation; Drug: Pembrolizumab
Sponsors: Dana-Farber Cancer Institute; Merck Sharp & Dohme LLC
Completed -
Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
Posted: March 22nd, 2017, 2:00pm GMT
Condition: Adenoid Cystic Carcinoma
Interventions: Radiation: Radiation; Drug: Pembrolizumab
Sponsors: Dana-Farber Cancer Institute; Merck Sharp & Dohme LLC
Completed -
Trail Evaluating Particle Therapy With or Without Apatinib for H&N Adenoid Cystic Carcinoma
Posted: October 24th, 2016, 2:00pm GMT
Condition: Adenoid Cystic Carcinoma
Interventions: Drug: Apatinib; Radiation: Particle Therapy
Sponsor: Shanghai Proton and Heavy Ion Center
Unknown status -
Chidamide for Advanced Cephalic and Cervical Adenocystic Carcinoma: Evaluation of Efficiency and Safety
Posted: August 30th, 2016, 2:00pm GMT
Condition: Adenocystic Carcinoma
Intervention: Drug: Chidamide
Sponsor: Dong mei
Unknown status -
Chidamide for Advanced Cephalic and Cervical Adenocystic Carcinoma: Evaluation of Efficiency and Safety
Posted: August 30th, 2016, 2:00pm GMT
Condition: Adenocystic Carcinoma
Intervention: Drug: Chidamide
Sponsor: Dong mei
Unknown status -
Lenvatinib in Recurrent and/or Metastatic Adenoid Cystic Carcinomas of the Salivary Glands: ACC-LEN14
Posted: August 10th, 2016, 2:00pm GMT
Condition: Adenoid Cystic Carcinomas of the Salivary Glands
Intervention: Drug: Lenvatinib
Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Completed -
Lenvatinib in Recurrent and/or Metastatic Adenoid Cystic Carcinomas of the Salivary Glands: ACC-LEN14
Posted: August 10th, 2016, 2:00pm GMT
Condition: Adenoid Cystic Carcinomas of the Salivary Glands
Intervention: Drug: Lenvatinib
Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Completed -
Study of Axitinib in Patients With Recurred or Metastatic Adenoid Cystic Carcinoma
Posted: August 8th, 2016, 2:00pm GMT
Condition: Recurrent ACC, metastaticACC, Unreaectable ACC
Interventions: Drug: Axitinib; Other: Observation
Sponsor: Seoul National University Hospital
Completed -
Study of Axitinib in Patients With Recurred or Metastatic Adenoid Cystic Carcinoma
Posted: August 8th, 2016, 2:00pm GMT
Condition: Recurrent ACC, metastaticACC, Unreaectable ACC
Interventions: Drug: Axitinib; Other: Observation
Sponsor: Seoul National University Hospital
Completed -
Randomized Carbon Ions vs Standard Radiotherapy for Radioresistant Tumors
Posted: July 20th, 2016, 2:00pm GMT
Condition: Malignant Tumors as Chordoma, Adenoid Cystic Carcinoma and Sarcoma
Interventions: Radiation: Carbon ions therapy; Radiation: Advanced external radiotherapy by Xrays or protons
Sponsor: Hospices Civils de Lyon
Recruiting -
Randomized Carbon Ions vs Standard Radiotherapy for Radioresistant Tumors
Posted: July 20th, 2016, 2:00pm GMT
Condition: Malignant Tumors as Chordoma, Adenoid Cystic Carcinoma and Sarcoma
Interventions: Radiation: Carbon ions therapy; Radiation: Advanced external radiotherapy by Xrays or protons
Sponsor: Hospices Civils de Lyon
Recruiting -
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Posted: July 15th, 2016, 2:00pm GMT
Conditions: Acinar Cell Carcinoma; Adenoid Cystic Carcinoma; Adrenal Cortical Carcinoma; Adrenal Gland Pheochromocytoma; Anal Canal Neuroendocrine Carcinoma; Anal Canal Undifferentiated Carcinoma; Angiosarcoma; Apocrine Neoplasm; Appendix Mucinous Adenocarcinoma; Bartholin Gland Transitional Cell Carcinoma; Basal Cell Carcinoma; Bladder Adenocarcinoma; Breast Metaplastic Carcinoma; Cervical Adenocarcinoma; Cholangiocarcinoma; Chordoma; Colorectal Squamous Cell Carcinoma; Desmoid Fibromatosis; Endometrial Transitional Cell Carcinoma; Endometrioid Adenocarcinoma; Esophageal Neuroendocrine Carcinoma; Esophageal Undifferentiated Carcinoma; Extrahepatic Bile Duct Carcinoma; Extramammary Paget Disease; Fallopian Tube Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fibromyxoid Tumor; Gallbladder Carcinoma; Gastric Neuroendocrine Carcinoma; Gastric Squamous Cell Carcinoma; Gastric Undifferentiated Carcinoma; Gastrointestinal Stromal Tumor; Gestational Trophoblastic Tumor; Giant Cell Carcinoma; Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type; Intestinal Neuroendocrine Carcinoma; Intrahepatic Cholangiocarcinoma; Lung Carcinoid Tumor; Lung Sarcomatoid Carcinoma; Major Salivary Gland Carcinoma; Malignant Odontogenic Neoplasm; Malignant Peripheral Nerve Sheath Tumor; Malignant Solid Neoplasm; Malignant Testicular Sex Cord-Stromal Tumor; Metastatic Malignant Neoplasm of Unknown Primary; Metastatic Pituitary Neuroendocrine Tumor; Minimally Invasive Lung Adenocarcinoma; Mixed Mesodermal (Mullerian) Tumor; Mucinous Adenocarcinoma; Mucinous Cystadenocarcinoma; Nasal Cavity Adenocarcinoma; Nasal Cavity Carcinoma; Nasopharyngeal Carcinoma; Nasopharyngeal Papillary Adenocarcinoma; Nasopharyngeal Undifferentiated Carcinoma; Oral Cavity Carcinoma; Oropharyngeal Undifferentiated Carcinoma; Ovarian Adenocarcinoma; Ovarian Germ Cell Tumor; Ovarian Mucinous Adenocarcinoma; Ovarian Squamous Cell Carcinoma; Ovarian Transitional Cell Carcinoma; Pancreatic Acinar Cell Carcinoma; Pancreatic Neuroendocrine Carcinoma; Paraganglioma; Paranasal Sinus Adenocarcinoma; Paranasal Sinus Carcinoma; Parathyroid Gland Carcinoma; PEComa; Peritoneal Mesothelioma; Placental Choriocarcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Pseudomyxoma Peritonei; Rare Disorder; Scrotal Squamous Cell Carcinoma; Seminal Vesicle Adenocarcinoma; Seminoma; Serous Cystadenocarcinoma; Small Intestinal Adenocarcinoma; Small Intestinal Squamous Cell Carcinoma; Spindle Cell Neoplasm; Squamous Cell Carcinoma of the Penis; Teratoma With Somatic-Type Malignancy; Testicular Non-Seminomatous Germ Cell Tumor; Thyroid Gland Carcinoma; Tracheal Carcinoma; Transitional Cell Carcinoma; Ureter Adenocarcinoma; Ureter Squamous Cell Carcinoma; Urethral Adenocarcinoma; Urethral Squamous Cell Carcinoma; Vaginal Adenocarcinoma; Vaginal Squamous Cell Carcinoma, Not Otherwise Specified; Vulvar Carcinoma
Interventions: Procedure: Biospecimen Collection; Biological: Ipilimumab; Biological: Nivolumab
Sponsor: National Cancer Institute (NCI)
Recruiting -
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Posted: July 15th, 2016, 2:00pm GMT
Conditions: Acinar Cell Carcinoma; Adenoid Cystic Carcinoma; Adrenal Cortical Carcinoma; Adrenal Gland Pheochromocytoma; Anal Canal Neuroendocrine Carcinoma; Anal Canal Undifferentiated Carcinoma; Angiosarcoma; Apocrine Neoplasm; Appendix Mucinous Adenocarcinoma; Bartholin Gland Transitional Cell Carcinoma; Basal Cell Carcinoma; Bladder Adenocarcinoma; Breast Metaplastic Carcinoma; Cervical Adenocarcinoma; Cholangiocarcinoma; Chordoma; Colorectal Squamous Cell Carcinoma; Desmoid Fibromatosis; Endometrial Transitional Cell Carcinoma; Endometrioid Adenocarcinoma; Esophageal Neuroendocrine Carcinoma; Esophageal Undifferentiated Carcinoma; Extrahepatic Bile Duct Carcinoma; Extramammary Paget Disease; Fallopian Tube Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fibromyxoid Tumor; Gallbladder Carcinoma; Gastric Neuroendocrine Carcinoma; Gastric Squamous Cell Carcinoma; Gastric Undifferentiated Carcinoma; Gastrointestinal Stromal Tumor; Gestational Trophoblastic Tumor; Giant Cell Carcinoma; Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type; Intestinal Neuroendocrine Carcinoma; Intrahepatic Cholangiocarcinoma; Lung Carcinoid Tumor; Lung Sarcomatoid Carcinoma; Major Salivary Gland Carcinoma; Malignant Odontogenic Neoplasm; Malignant Peripheral Nerve Sheath Tumor; Malignant Solid Neoplasm; Malignant Testicular Sex Cord-Stromal Tumor; Metastatic Malignant Neoplasm of Unknown Primary; Metastatic Pituitary Neuroendocrine Tumor; Minimally Invasive Lung Adenocarcinoma; Mixed Mesodermal (Mullerian) Tumor; Mucinous Adenocarcinoma; Mucinous Cystadenocarcinoma; Nasal Cavity Adenocarcinoma; Nasal Cavity Carcinoma; Nasopharyngeal Carcinoma; Nasopharyngeal Papillary Adenocarcinoma; Nasopharyngeal Undifferentiated Carcinoma; Oral Cavity Carcinoma; Oropharyngeal Undifferentiated Carcinoma; Ovarian Adenocarcinoma; Ovarian Germ Cell Tumor; Ovarian Mucinous Adenocarcinoma; Ovarian Squamous Cell Carcinoma; Ovarian Transitional Cell Carcinoma; Pancreatic Acinar Cell Carcinoma; Pancreatic Neuroendocrine Carcinoma; Paraganglioma; Paranasal Sinus Adenocarcinoma; Paranasal Sinus Carcinoma; Parathyroid Gland Carcinoma; PEComa; Peritoneal Mesothelioma; Placental Choriocarcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Pseudomyxoma Peritonei; Rare Disorder; Scrotal Squamous Cell Carcinoma; Seminal Vesicle Adenocarcinoma; Seminoma; Serous Cystadenocarcinoma; Small Intestinal Adenocarcinoma; Small Intestinal Squamous Cell Carcinoma; Spindle Cell Neoplasm; Squamous Cell Carcinoma of the Penis; Teratoma With Somatic-Type Malignancy; Testicular Non-Seminomatous Germ Cell Tumor; Thyroid Gland Carcinoma; Tracheal Carcinoma; Transitional Cell Carcinoma; Ureter Adenocarcinoma; Ureter Squamous Cell Carcinoma; Urethral Adenocarcinoma; Urethral Squamous Cell Carcinoma; Vaginal Adenocarcinoma; Vaginal Squamous Cell Carcinoma, Not Otherwise Specified; Vulvar Carcinoma
Interventions: Procedure: Biospecimen Collection; Biological: Ipilimumab; Biological: Nivolumab
Sponsor: National Cancer Institute (NCI)
Recruiting -
Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma
Posted: May 23rd, 2016, 2:00pm GMT
Condition: Adenoid Cystic Carcinoma
Intervention: Drug: Lenvatinib
Sponsors: Memorial Sloan Kettering Cancer Center; Eisai Inc.
Active, not recruiting -
Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma
Posted: May 23rd, 2016, 2:00pm GMT
Condition: Adenoid Cystic Carcinoma
Intervention: Drug: Lenvatinib
Sponsors: Memorial Sloan Kettering Cancer Center; Eisai Inc.
Active, not recruiting -
A Study of Apatinib in Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck
Posted: May 17th, 2016, 2:00pm GMT
Condition: Adenoid Cystic Carcinoma
Intervention: Drug: Apatinib Mesylate
Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Unknown status -
Compassionate Use of Brontictuzumab for Adenoid Cystic Carcinoma (ACC)
Posted: January 25th, 2016, 3:00pm GMT
Condition: Adenoid Cystic Carcinoma
Intervention: Drug: Brontictuzumab
Sponsor: M.D. Anderson Cancer Center
Completed -
Compassionate Use of Brontictuzumab for Adenoid Cystic Carcinoma (ACC)
Posted: January 25th, 2016, 3:00pm GMT
Condition: Adenoid Cystic Carcinoma
Intervention: Drug: Brontictuzumab
Sponsor: M.D. Anderson Cancer Center
Completed -
Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy
Posted: April 25th, 2014, 2:00pm GMT
Conditions: Mucositis; Oral Complications; Recurrent Adenoid Cystic Carcinoma of the Oral Cavity; Recurrent Basal Cell Carcinoma of the Lip; Recurrent Lymphoepithelioma of the Nasopharynx; Recurrent Lymphoepithelioma of the Oropharynx; Recurrent Mucoepidermoid Carcinoma of the Oral Cavity; Recurrent Salivary Gland Cancer; Recurrent Squamous Cell Carcinoma of the Larynx; Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity; Recurrent Squamous Cell Carcinoma of the Nasopharynx; Recurrent Squamous Cell Carcinoma of the Oropharynx; Recurrent Verrucous Carcinoma of the Larynx; Recurrent Verrucous Carcinoma of the Oral Cavity; Stage I Adenoid Cystic Carcinoma of the Oral Cavity; Stage I Basal Cell Carcinoma of the Lip; Stage I Lymphoepithelioma of the Nasopharynx; Stage I Lymphoepithelioma of the Oropharynx; Stage I Mucoepidermoid Carcinoma of the Oral Cavity; Stage I Salivary Gland Cancer; Stage I Squamous Cell Carcinoma of the Larynx; Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage I Squamous Cell Carcinoma of the Nasopharynx; Stage I Squamous Cell Carcinoma of the Oropharynx; Stage I Verrucous Carcinoma of the Larynx; Stage I Verrucous Carcinoma of the Oral Cavity; Stage II Adenoid Cystic Carcinoma of the Oral Cavity; Stage II Basal Cell Carcinoma of the Lip; Stage II Lymphoepithelioma of the Nasopharynx; Stage II Lymphoepithelioma of the Oropharynx; Stage II Mucoepidermoid Carcinoma of the Oral Cavity; Stage II Salivary Gland Cancer; Stage II Squamous Cell Carcinoma of the Larynx; Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage II Squamous Cell Carcinoma of the Nasopharynx; Stage II Squamous Cell Carcinoma of the Oropharynx; Stage II Verrucous Carcinoma of the Larynx; Stage II Verrucous Carcinoma of the Oral Cavity; Stage III Adenoid Cystic Carcinoma of the Oral Cavity; Stage III Basal Cell Carcinoma of the Lip; Stage III Lymphoepithelioma of the Nasopharynx; Stage III Lymphoepithelioma of the Oropharynx; Stage III Mucoepidermoid Carcinoma of the Oral Cavity; Stage III Salivary Gland Cancer; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Nasopharynx; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Lymphoepithelioma of the Nasopharynx; Stage IV Squamous Cell Carcinoma of the Nasopharynx; Stage IVA Adenoid Cystic Carcinoma of the Oral Cavity; Stage IVA Basal Cell Carcinoma of the Lip; Stage IVA Lymphoepithelioma of the Oropharynx; Stage IVA Mucoepidermoid Carcinoma of the Oral Cavity; Stage IVA Salivary Gland Cancer; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Adenoid Cystic Carcinoma of the Oral Cavity; Stage IVB Basal Cell Carcinoma of the Lip; Stage IVB Lymphoepithelioma of the Oropharynx; Stage IVB Mucoepidermoid Carcinoma of the Oral Cavity; Stage IVB Salivary Gland Cancer; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Stage IVC Adenoid Cystic Carcinoma of the Oral Cavity; Stage IVC Basal Cell Carcinoma of the Lip; Stage IVC Lymphoepithelioma of the Oropharynx; Stage IVC Mucoepidermoid Carcinoma of the Oral Cavity; Stage IVC Salivary Gland Cancer; Stage IVC Squamous Cell Carcinoma of the Larynx; Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVC Squamous Cell Carcinoma of the Oropharynx; Stage IVC Verrucous Carcinoma of the Larynx; Stage IVC Verrucous Carcinoma of the Oral Cavity; Tongue Cancer
Interventions: Drug: acetylcysteine; Other: placebo; Other: quality-of-life assessment; Other: questionnaire administration
Sponsors: Mayo Clinic; National Cancer Institute (NCI)
Completed -
Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy
Posted: April 25th, 2014, 2:00pm GMT
Conditions: Mucositis; Oral Complications; Recurrent Adenoid Cystic Carcinoma of the Oral Cavity; Recurrent Basal Cell Carcinoma of the Lip; Recurrent Lymphoepithelioma of the Nasopharynx; Recurrent Lymphoepithelioma of the Oropharynx; Recurrent Mucoepidermoid Carcinoma of the Oral Cavity; Recurrent Salivary Gland Cancer; Recurrent Squamous Cell Carcinoma of the Larynx; Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity; Recurrent Squamous Cell Carcinoma of the Nasopharynx; Recurrent Squamous Cell Carcinoma of the Oropharynx; Recurrent Verrucous Carcinoma of the Larynx; Recurrent Verrucous Carcinoma of the Oral Cavity; Stage I Adenoid Cystic Carcinoma of the Oral Cavity; Stage I Basal Cell Carcinoma of the Lip; Stage I Lymphoepithelioma of the Nasopharynx; Stage I Lymphoepithelioma of the Oropharynx; Stage I Mucoepidermoid Carcinoma of the Oral Cavity; Stage I Salivary Gland Cancer; Stage I Squamous Cell Carcinoma of the Larynx; Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage I Squamous Cell Carcinoma of the Nasopharynx; Stage I Squamous Cell Carcinoma of the Oropharynx; Stage I Verrucous Carcinoma of the Larynx; Stage I Verrucous Carcinoma of the Oral Cavity; Stage II Adenoid Cystic Carcinoma of the Oral Cavity; Stage II Basal Cell Carcinoma of the Lip; Stage II Lymphoepithelioma of the Nasopharynx; Stage II Lymphoepithelioma of the Oropharynx; Stage II Mucoepidermoid Carcinoma of the Oral Cavity; Stage II Salivary Gland Cancer; Stage II Squamous Cell Carcinoma of the Larynx; Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage II Squamous Cell Carcinoma of the Nasopharynx; Stage II Squamous Cell Carcinoma of the Oropharynx; Stage II Verrucous Carcinoma of the Larynx; Stage II Verrucous Carcinoma of the Oral Cavity; Stage III Adenoid Cystic Carcinoma of the Oral Cavity; Stage III Basal Cell Carcinoma of the Lip; Stage III Lymphoepithelioma of the Nasopharynx; Stage III Lymphoepithelioma of the Oropharynx; Stage III Mucoepidermoid Carcinoma of the Oral Cavity; Stage III Salivary Gland Cancer; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Nasopharynx; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Lymphoepithelioma of the Nasopharynx; Stage IV Squamous Cell Carcinoma of the Nasopharynx; Stage IVA Adenoid Cystic Carcinoma of the Oral Cavity; Stage IVA Basal Cell Carcinoma of the Lip; Stage IVA Lymphoepithelioma of the Oropharynx; Stage IVA Mucoepidermoid Carcinoma of the Oral Cavity; Stage IVA Salivary Gland Cancer; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Adenoid Cystic Carcinoma of the Oral Cavity; Stage IVB Basal Cell Carcinoma of the Lip; Stage IVB Lymphoepithelioma of the Oropharynx; Stage IVB Mucoepidermoid Carcinoma of the Oral Cavity; Stage IVB Salivary Gland Cancer; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Stage IVC Adenoid Cystic Carcinoma of the Oral Cavity; Stage IVC Basal Cell Carcinoma of the Lip; Stage IVC Lymphoepithelioma of the Oropharynx; Stage IVC Mucoepidermoid Carcinoma of the Oral Cavity; Stage IVC Salivary Gland Cancer; Stage IVC Squamous Cell Carcinoma of the Larynx; Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVC Squamous Cell Carcinoma of the Oropharynx; Stage IVC Verrucous Carcinoma of the Larynx; Stage IVC Verrucous Carcinoma of the Oral Cavity; Tongue Cancer
Interventions: Drug: acetylcysteine; Other: placebo; Other: quality-of-life assessment; Other: questionnaire administration
Sponsors: Mayo Clinic; National Cancer Institute (NCI)
Completed -
Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Posted: March 28th, 2014, 2:00pm GMT
Condition: Adenoid Cystic Carcinoma
Intervention: Drug: Regorafenib
Sponsors: Memorial Sloan Kettering Cancer Center; Bayer
Active, not recruiting -
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
Posted: March 7th, 2013, 3:00pm GMT
Conditions: Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Male Breast Cancer; Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma; Recurrent Adenoid Cystic Carcinoma of the Oral Cavity; Recurrent Adult Brain Tumor; Recurrent Basal Cell Carcinoma of the Lip; Recurrent Colon Cancer; Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity; Recurrent Hypopharyngeal Cancer; Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity; Recurrent Laryngeal Cancer; Recurrent Lip and Oral Cavity Cancer; Recurrent Lymphoepithelioma of the Nasopharynx; Recurrent Lymphoepithelioma of the Oropharynx; Recurrent Metastatic Squamous Neck Cancer With Occult Primary; Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity; Recurrent Mucoepidermoid Carcinoma of the Oral Cavity; Recurrent Nasopharyngeal Cancer; Recurrent Non-small Cell Lung Cancer; Recurrent Oropharyngeal Cancer; Recurrent Pancreatic Cancer; Recurrent Paranasal Sinus and Nasal Cavity Cancer; Recurrent Rectal Cancer; Recurrent Renal Cell Cancer; Recurrent Salivary Gland Cancer; Stage IIIA Breast Cancer; Stage IIIA Non-small Cell Lung Cancer; Stage IIIB Breast Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer; Stage IV Non-small Cell Lung Cancer; Stage IV Pancreatic Cancer; Stage IV Renal Cell Cancer; Stage IVA Colon Cancer; Stage IVA Rectal Cancer; Stage IVA Salivary Gland Cancer; Stage IVB Colon Cancer; Stage IVB Salivary Gland Cancer; Stage IVC Salivary Gland Cancer; Tongue Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: 18F-fludeoxyglucose (18F-FDG); Drug: 18F-FPPRGD2
Sponsors: Sanjiv Sam Gambhir; National Cancer Institute (NCI)
Completed -
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
Posted: March 7th, 2013, 3:00pm GMT
Conditions: Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Male Breast Cancer; Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma; Recurrent Adenoid Cystic Carcinoma of the Oral Cavity; Recurrent Adult Brain Tumor; Recurrent Basal Cell Carcinoma of the Lip; Recurrent Colon Cancer; Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity; Recurrent Hypopharyngeal Cancer; Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity; Recurrent Laryngeal Cancer; Recurrent Lip and Oral Cavity Cancer; Recurrent Lymphoepithelioma of the Nasopharynx; Recurrent Lymphoepithelioma of the Oropharynx; Recurrent Metastatic Squamous Neck Cancer With Occult Primary; Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity; Recurrent Mucoepidermoid Carcinoma of the Oral Cavity; Recurrent Nasopharyngeal Cancer; Recurrent Non-small Cell Lung Cancer; Recurrent Oropharyngeal Cancer; Recurrent Pancreatic Cancer; Recurrent Paranasal Sinus and Nasal Cavity Cancer; Recurrent Rectal Cancer; Recurrent Renal Cell Cancer; Recurrent Salivary Gland Cancer; Stage IIIA Breast Cancer; Stage IIIA Non-small Cell Lung Cancer; Stage IIIB Breast Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer; Stage IV Non-small Cell Lung Cancer; Stage IV Pancreatic Cancer; Stage IV Renal Cell Cancer; Stage IVA Colon Cancer; Stage IVA Rectal Cancer; Stage IVA Salivary Gland Cancer; Stage IVB Colon Cancer; Stage IVB Salivary Gland Cancer; Stage IVC Salivary Gland Cancer; Tongue Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: 18F-fludeoxyglucose (18F-FDG); Drug: 18F-FPPRGD2
Sponsors: Sanjiv Sam Gambhir; National Cancer Institute (NCI)
Completed -
A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands
Posted: September 3rd, 2012, 2:00pm GMT
Conditions: Recurrent Adenoid Cystic Carcinoma of the Salivary Glands; Metastatic Adenoid Cystic Carcinoma of the Salivary Glands; Salivary Gland Cancers; ACC
Intervention: Drug: Dovitinib
Sponsors: Ontario Clinical Oncology Group (OCOG); Novartis Pharmaceuticals
Completed -
A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands
Posted: September 3rd, 2012, 2:00pm GMT
Conditions: Recurrent Adenoid Cystic Carcinoma of the Salivary Glands; Metastatic Adenoid Cystic Carcinoma of the Salivary Glands; Salivary Gland Cancers; ACC
Intervention: Drug: Dovitinib
Sponsors: Ontario Clinical Oncology Group (OCOG); Novartis Pharmaceuticals
Completed -
Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer
Posted: July 11th, 2012, 2:00pm GMT
Conditions: Recurrent Adenoid Cystic Carcinoma of the Oral Cavity; Recurrent Basal Cell Carcinoma of the Lip; Recurrent Colon Cancer; Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity; Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity; Recurrent Lymphoepithelioma of the Nasopharynx; Recurrent Lymphoepithelioma of the Oropharynx; Recurrent Metastatic Squamous Neck Cancer With Occult Primary; Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity; Recurrent Mucoepidermoid Carcinoma of the Oral Cavity; Recurrent Salivary Gland Cancer; Recurrent Squamous Cell Carcinoma of the Hypopharynx; Recurrent Squamous Cell Carcinoma of the Larynx; Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity; Recurrent Squamous Cell Carcinoma of the Nasopharynx; Recurrent Squamous Cell Carcinoma of the Oropharynx; Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Recurrent Verrucous Carcinoma of the Larynx; Recurrent Verrucous Carcinoma of the Oral Cavity; Stage IV Adenoid Cystic Carcinoma of the Oral Cavity; Stage IV Basal Cell Carcinoma of the Lip; Stage IV Lymphoepithelioma of the Nasopharynx; Stage IV Lymphoepithelioma of the Oropharynx; Stage IV Mucoepidermoid Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IV Squamous Cell Carcinoma of the Nasopharynx; Stage IV Squamous Cell Carcinoma of the Oropharynx; Stage IV Verrucous Carcinoma of the Larynx; Stage IV Verrucous Carcinoma of the Oral Cavity; Stage IVA Colon Cancer; Stage IVA Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity; Stage IVA Inverted Papilloma of the Paranasal Sinus and Nasal Cavity; Stage IVA Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity; Stage IVA Salivary Gland Cancer; Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage IVB Colon Cancer; Stage IVB Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity; Stage IVB Inverted Papilloma of the Paranasal Sinus and Nasal Cavity; Stage IVB Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity; Stage IVB Salivary Gland Cancer; Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage IVC Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity; Stage IVC Inverted Papilloma of the Paranasal Sinus and Nasal Cavity; Stage IVC Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity; Stage IVC Salivary Gland Cancer; Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Tongue Cancer
Interventions: Drug: everolimus; Biological: cetuximab; Other: pharmacological study; Other: laboratory biomarker analysis
Sponsors: Fox Chase Cancer Center; National Cancer Institute (NCI)
Completed -
Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer
Posted: July 11th, 2012, 2:00pm GMT
Conditions: Recurrent Adenoid Cystic Carcinoma of the Oral Cavity; Recurrent Basal Cell Carcinoma of the Lip; Recurrent Colon Cancer; Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity; Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity; Recurrent Lymphoepithelioma of the Nasopharynx; Recurrent Lymphoepithelioma of the Oropharynx; Recurrent Metastatic Squamous Neck Cancer With Occult Primary; Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity; Recurrent Mucoepidermoid Carcinoma of the Oral Cavity; Recurrent Salivary Gland Cancer; Recurrent Squamous Cell Carcinoma of the Hypopharynx; Recurrent Squamous Cell Carcinoma of the Larynx; Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity; Recurrent Squamous Cell Carcinoma of the Nasopharynx; Recurrent Squamous Cell Carcinoma of the Oropharynx; Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Recurrent Verrucous Carcinoma of the Larynx; Recurrent Verrucous Carcinoma of the Oral Cavity; Stage IV Adenoid Cystic Carcinoma of the Oral Cavity; Stage IV Basal Cell Carcinoma of the Lip; Stage IV Lymphoepithelioma of the Nasopharynx; Stage IV Lymphoepithelioma of the Oropharynx; Stage IV Mucoepidermoid Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IV Squamous Cell Carcinoma of the Nasopharynx; Stage IV Squamous Cell Carcinoma of the Oropharynx; Stage IV Verrucous Carcinoma of the Larynx; Stage IV Verrucous Carcinoma of the Oral Cavity; Stage IVA Colon Cancer; Stage IVA Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity; Stage IVA Inverted Papilloma of the Paranasal Sinus and Nasal Cavity; Stage IVA Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity; Stage IVA Salivary Gland Cancer; Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage IVB Colon Cancer; Stage IVB Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity; Stage IVB Inverted Papilloma of the Paranasal Sinus and Nasal Cavity; Stage IVB Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity; Stage IVB Salivary Gland Cancer; Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage IVC Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity; Stage IVC Inverted Papilloma of the Paranasal Sinus and Nasal Cavity; Stage IVC Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity; Stage IVC Salivary Gland Cancer; Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Tongue Cancer
Interventions: Drug: everolimus; Biological: cetuximab; Other: pharmacological study; Other: laboratory biomarker analysis
Sponsors: Fox Chase Cancer Center; National Cancer Institute (NCI)
Completed -
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
Posted: May 24th, 2012, 2:00pm GMT
Conditions: Recurrent Oral Cavity Adenoid Cystic Carcinoma; Recurrent Salivary Gland Carcinoma; Salivary Gland Adenoid Cystic Carcinoma; Stage IVA Major Salivary Gland Cancer AJCC v7; Stage IVA Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7; Stage IVB Major Salivary Gland Cancer AJCC v7; Stage IVB Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7; Stage IVC Major Salivary Gland Cancer AJCC v7; Stage IVC Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7
Interventions: Drug: Akt Inhibitor MK2206; Other: Laboratory Biomarker Analysis
Sponsor: National Cancer Institute (NCI)
Completed -
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
Posted: May 24th, 2012, 2:00pm GMT
Conditions: Recurrent Oral Cavity Adenoid Cystic Carcinoma; Recurrent Salivary Gland Carcinoma; Salivary Gland Adenoid Cystic Carcinoma; Stage IVA Major Salivary Gland Cancer AJCC v7; Stage IVA Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7; Stage IVB Major Salivary Gland Cancer AJCC v7; Stage IVB Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7; Stage IVC Major Salivary Gland Cancer AJCC v7; Stage IVC Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7
Interventions: Drug: Akt Inhibitor MK2206; Other: Laboratory Biomarker Analysis
Sponsor: National Cancer Institute (NCI)
Completed -
Intensity-Modulated or Proton Radiation Therapy for Sinonasal Malignancy
Posted: April 27th, 2012, 2:00pm GMT
Conditions: Adenoid Cystic Carcinoma; Squamous Cell Carcinoma; Sinonasal Carcinoma; Sinonasal Undifferentiated Carcinoma; Mucoepidermoid Carcinoma; Schneiderian Carcinoma; Myoepithelial Carcinoma; Esthesioneuroblastoma; Melanoma
Interventions: Radiation: Proton radiation therapy; Radiation: Intensity-modulated radiotherapy
Sponsors: Massachusetts General Hospital; National Institutes of Health (NIH); National Cancer Institute (NCI)
Recruiting -
Intensity-Modulated or Proton Radiation Therapy for Sinonasal Malignancy
Posted: April 27th, 2012, 2:00pm GMT
Conditions: Adenoid Cystic Carcinoma; Squamous Cell Carcinoma; Sinonasal Carcinoma; Sinonasal Undifferentiated Carcinoma; Mucoepidermoid Carcinoma; Schneiderian Carcinoma; Myoepithelial Carcinoma; Esthesioneuroblastoma; Melanoma
Interventions: Radiation: Proton radiation therapy; Radiation: Intensity-modulated radiotherapy
Sponsors: Massachusetts General Hospital; National Institutes of Health (NIH); National Cancer Institute (NCI)
Recruiting -
Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Posted: March 20th, 2012, 2:00pm GMT
Condition: Adenoid Cystic Carcinoma
Intervention: Drug: AG-013736 (AXITINIB)
Sponsors: Memorial Sloan Kettering Cancer Center; National Comprehensive Cancer Network; Pfizer
Completed -
Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Posted: March 20th, 2012, 2:00pm GMT
Condition: Adenoid Cystic Carcinoma
Intervention: Drug: AG-013736 (AXITINIB)
Sponsors: Memorial Sloan Kettering Cancer Center; National Comprehensive Cancer Network; Pfizer
Completed -
Study of Dovitinib (TKI258) in Adenoid Cystic Carcinoma
Posted: February 2nd, 2012, 3:00pm GMT
Condition: Adenoid Cystic Carcinoma
Intervention: Drug: Dovitinib (TKI258)
Sponsors: University of Virginia; Novartis Pharmaceuticals
Completed -
Study of Dovitinib (TKI258) in Adenoid Cystic Carcinoma
Posted: February 2nd, 2012, 3:00pm GMT
Condition: Adenoid Cystic Carcinoma
Intervention: Drug: Dovitinib (TKI258)
Sponsors: University of Virginia; Novartis Pharmaceuticals
Completed -
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
Posted: November 17th, 2011, 3:00pm GMT
Conditions: Recurrent Adenoid Cystic Carcinoma of the Oral Cavity; Recurrent Mucoepidermoid Carcinoma of the Oral Cavity; Recurrent Squamous Cell Carcinoma of the Hypopharynx; Recurrent Squamous Cell Carcinoma of the Larynx; Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity; Recurrent Verrucous Carcinoma of the Larynx; Recurrent Verrucous Carcinoma of the Oral Cavity; Stage 0 Hypopharyngeal Cancer; Stage 0 Laryngeal Cancer; Stage 0 Lip and Oral Cavity Cancer; Stage I Adenoid Cystic Carcinoma of the Oral Cavity; Stage I Mucoepidermoid Carcinoma of the Oral Cavity; Stage I Squamous Cell Carcinoma of the Hypopharynx; Stage I Squamous Cell Carcinoma of the Larynx; Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage I Verrucous Carcinoma of the Larynx; Stage I Verrucous Carcinoma of the Oral Cavity; Stage II Adenoid Cystic Carcinoma of the Oral Cavity; Stage II Mucoepidermoid Carcinoma of the Oral Cavity; Stage II Squamous Cell Carcinoma of the Hypopharynx; Stage II Squamous Cell Carcinoma of the Larynx; Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage II Verrucous Carcinoma of the Larynx; Stage II Verrucous Carcinoma of the Oral Cavity; Stage III Adenoid Cystic Carcinoma of the Oral Cavity; Stage III Mucoepidermoid Carcinoma of the Oral Cavity; Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IVA Adenoid Cystic Carcinoma of the Oral Cavity; Stage IVA Mucoepidermoid Carcinoma of the Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Adenoid Cystic Carcinoma of the Oral Cavity; Stage IVB Mucoepidermoid Carcinoma of the Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Stage IVC Adenoid Cystic Carcinoma of the Oral Cavity; Stage IVC Mucoepidermoid Carcinoma of the Oral Cavity; Stage IVC Squamous Cell Carcinoma of the Larynx; Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVC Verrucous Carcinoma of the Larynx; Stage IVC Verrucous Carcinoma of the Oral Cavity; Tongue Cancer
Interventions: Procedure: transoral robotic surgery; Procedure: quality of life assessment
Sponsor: Ohio State University Comprehensive Cancer Center
Recruiting -
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
Posted: November 17th, 2011, 3:00pm GMT
Conditions: Recurrent Adenoid Cystic Carcinoma of the Oral Cavity; Recurrent Mucoepidermoid Carcinoma of the Oral Cavity; Recurrent Squamous Cell Carcinoma of the Hypopharynx; Recurrent Squamous Cell Carcinoma of the Larynx; Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity; Recurrent Verrucous Carcinoma of the Larynx; Recurrent Verrucous Carcinoma of the Oral Cavity; Stage 0 Hypopharyngeal Cancer; Stage 0 Laryngeal Cancer; Stage 0 Lip and Oral Cavity Cancer; Stage I Adenoid Cystic Carcinoma of the Oral Cavity; Stage I Mucoepidermoid Carcinoma of the Oral Cavity; Stage I Squamous Cell Carcinoma of the Hypopharynx; Stage I Squamous Cell Carcinoma of the Larynx; Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage I Verrucous Carcinoma of the Larynx; Stage I Verrucous Carcinoma of the Oral Cavity; Stage II Adenoid Cystic Carcinoma of the Oral Cavity; Stage II Mucoepidermoid Carcinoma of the Oral Cavity; Stage II Squamous Cell Carcinoma of the Hypopharynx; Stage II Squamous Cell Carcinoma of the Larynx; Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage II Verrucous Carcinoma of the Larynx; Stage II Verrucous Carcinoma of the Oral Cavity; Stage III Adenoid Cystic Carcinoma of the Oral Cavity; Stage III Mucoepidermoid Carcinoma of the Oral Cavity; Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IVA Adenoid Cystic Carcinoma of the Oral Cavity; Stage IVA Mucoepidermoid Carcinoma of the Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Adenoid Cystic Carcinoma of the Oral Cavity; Stage IVB Mucoepidermoid Carcinoma of the Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Stage IVC Adenoid Cystic Carcinoma of the Oral Cavity; Stage IVC Mucoepidermoid Carcinoma of the Oral Cavity; Stage IVC Squamous Cell Carcinoma of the Larynx; Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVC Verrucous Carcinoma of the Larynx; Stage IVC Verrucous Carcinoma of the Oral Cavity; Tongue Cancer
Interventions: Procedure: transoral robotic surgery; Procedure: quality of life assessment
Sponsor: Ohio State University Comprehensive Cancer Center
Recruiting -
Dovitinib in Adenoid Cystic Carcinoma
Posted: August 16th, 2011, 2:00pm GMT
Condition: Adenoid Cystic Carcinoma
Intervention: Drug: TKI258 (Dovitinib):
Sponsor: Seoul National University Hospital
Completed -
Transoral Robotic Surgery in Treating Patients With Benign or Stage I-IV Head and Neck Cancer
Posted: December 7th, 2010, 3:00pm GMT
Conditions: Recurrent Adenoid Cystic Carcinoma of the Oral Cavity; Recurrent Lymphoepithelioma of the Nasopharynx; Recurrent Lymphoepithelioma of the Oropharynx; Recurrent Mucoepidermoid Carcinoma of the Oral Cavity; Recurrent Squamous Cell Carcinoma of the Hypopharynx; Recurrent Squamous Cell Carcinoma of the Larynx; Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity; Recurrent Squamous Cell Carcinoma of the Nasopharynx; Recurrent Squamous Cell Carcinoma of the Oropharynx; Recurrent Verrucous Carcinoma of the Larynx; Recurrent Verrucous Carcinoma of the Oral Cavity; Stage I Adenoid Cystic Carcinoma of the Oral Cavity; Stage I Lymphoepithelioma of the Nasopharynx; Stage I Lymphoepithelioma of the Oropharynx; Stage I Mucoepidermoid Carcinoma of the Oral Cavity; Stage I Squamous Cell Carcinoma of the Hypopharynx; Stage I Squamous Cell Carcinoma of the Larynx; Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage I Squamous Cell Carcinoma of the Nasopharynx; Stage I Squamous Cell Carcinoma of the Oropharynx; Stage I Verrucous Carcinoma of the Larynx; Stage I Verrucous Carcinoma of the Oral Cavity; Stage II Adenoid Cystic Carcinoma of the Oral Cavity; Stage II Lymphoepithelioma of the Nasopharynx; Stage II Lymphoepithelioma of the Oropharynx; Stage II Mucoepidermoid Carcinoma of the Oral Cavity; Stage II Squamous Cell Carcinoma of the Hypopharynx; Stage II Squamous Cell Carcinoma of the Larynx; Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage II Squamous Cell Carcinoma of the Nasopharynx; Stage II Squamous Cell Carcinoma of the Oropharynx; Stage II Verrucous Carcinoma of the Larynx; Stage II Verrucous Carcinoma of the Oral Cavity; Stage III Adenoid Cystic Carcinoma of the Oral Cavity; Stage III Lymphoepithelioma of the Nasopharynx; Stage III Lymphoepithelioma of the Oropharynx; Stage III Mucoepidermoid Carcinoma of the Oral Cavity; Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Nasopharynx; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Adenoid Cystic Carcinoma of the Oral Cavity; Stage IV Lymphoepithelioma of the Nasopharynx; Stage IV Lymphoepithelioma of the Oropharynx; Stage IV Mucoepidermoid Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IV Squamous Cell Carcinoma of the Nasopharynx; Stage IV Squamous Cell Carcinoma of the Oropharynx; Stage IV Verrucous Carcinoma of the Larynx; Stage IV Verrucous Carcinoma of the Oral Cavity
Interventions: Procedure: transoral robotic surgery; Other: laboratory biomarker analysis; Procedure: quality-of-life assessment
Sponsors: City of Hope Medical Center; National Cancer Institute (NCI)
Terminated -
Transoral Robotic Surgery in Treating Patients With Benign or Stage I-IV Head and Neck Cancer
Posted: December 7th, 2010, 3:00pm GMT
Conditions: Recurrent Adenoid Cystic Carcinoma of the Oral Cavity; Recurrent Lymphoepithelioma of the Nasopharynx; Recurrent Lymphoepithelioma of the Oropharynx; Recurrent Mucoepidermoid Carcinoma of the Oral Cavity; Recurrent Squamous Cell Carcinoma of the Hypopharynx; Recurrent Squamous Cell Carcinoma of the Larynx; Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity; Recurrent Squamous Cell Carcinoma of the Nasopharynx; Recurrent Squamous Cell Carcinoma of the Oropharynx; Recurrent Verrucous Carcinoma of the Larynx; Recurrent Verrucous Carcinoma of the Oral Cavity; Stage I Adenoid Cystic Carcinoma of the Oral Cavity; Stage I Lymphoepithelioma of the Nasopharynx; Stage I Lymphoepithelioma of the Oropharynx; Stage I Mucoepidermoid Carcinoma of the Oral Cavity; Stage I Squamous Cell Carcinoma of the Hypopharynx; Stage I Squamous Cell Carcinoma of the Larynx; Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage I Squamous Cell Carcinoma of the Nasopharynx; Stage I Squamous Cell Carcinoma of the Oropharynx; Stage I Verrucous Carcinoma of the Larynx; Stage I Verrucous Carcinoma of the Oral Cavity; Stage II Adenoid Cystic Carcinoma of the Oral Cavity; Stage II Lymphoepithelioma of the Nasopharynx; Stage II Lymphoepithelioma of the Oropharynx; Stage II Mucoepidermoid Carcinoma of the Oral Cavity; Stage II Squamous Cell Carcinoma of the Hypopharynx; Stage II Squamous Cell Carcinoma of the Larynx; Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage II Squamous Cell Carcinoma of the Nasopharynx; Stage II Squamous Cell Carcinoma of the Oropharynx; Stage II Verrucous Carcinoma of the Larynx; Stage II Verrucous Carcinoma of the Oral Cavity; Stage III Adenoid Cystic Carcinoma of the Oral Cavity; Stage III Lymphoepithelioma of the Nasopharynx; Stage III Lymphoepithelioma of the Oropharynx; Stage III Mucoepidermoid Carcinoma of the Oral Cavity; Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Nasopharynx; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Adenoid Cystic Carcinoma of the Oral Cavity; Stage IV Lymphoepithelioma of the Nasopharynx; Stage IV Lymphoepithelioma of the Oropharynx; Stage IV Mucoepidermoid Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IV Squamous Cell Carcinoma of the Nasopharynx; Stage IV Squamous Cell Carcinoma of the Oropharynx; Stage IV Verrucous Carcinoma of the Larynx; Stage IV Verrucous Carcinoma of the Oral Cavity
Interventions: Procedure: transoral robotic surgery; Other: laboratory biomarker analysis; Procedure: quality-of-life assessment
Sponsors: City of Hope Medical Center; National Cancer Institute (NCI)
Terminated -
Study of Everolimus (RAD001) in Combination With Lenalidomide
Posted: October 11th, 2010, 2:00pm GMT
Conditions: Solid Organ Malignancies; Adenoidcystic Carcinoma; Neuroendocrine Tumors
Interventions: Drug: Lenalidomide; Drug: Everolimus
Sponsors: Emory University; Celgene; Novartis
Completed -
Study of Everolimus (RAD001) in Combination With Lenalidomide
Posted: October 11th, 2010, 2:00pm GMT
Conditions: Solid Organ Malignancies; Adenoidcystic Carcinoma; Neuroendocrine Tumors
Interventions: Drug: Lenalidomide; Drug: Everolimus
Sponsors: Emory University; Celgene; Novartis
Completed